Table 1. Patients’ characteristics.

	GvHD within d100				Overall N=115
	NO N=38		YES N=77
Median age at HSCT, years (range)	10.2 (2.2, 17.9)		9.3 (0.4, 22.0)		9.5 (0.4, 22.0)
Sex, n. (%)
Female	17	44.7	20	26.0	37	32.2
Male	21	55.3	57	74.0	78	67.8
Disease at HSCT, n. (%)
Acute lymphoblastic leukemia	22	57.9	46	59.7	68	59.1
Acute myeloid leukemia	11	28.9	15	19.5	26	22.6
Chronic myeloid leukemia	1	2.6	5	6.5	6	5.2
Myelodysplastic syndrome	0	0.0	5	6.5	5	2.6
Non-Hodgkin lymphoma	2	5.3	2	2.6	4	4.4
Hodgkin lymphoma	2	5.3	1	1.3	3	3.5
Others	0	0.0	3	3.9	3	2.6
Graft source, n. (%)
Bone Marrow	28	73.6	63	81.8	91	79.1
Peripheral blood stem cells	5	13.2	12	15.6	17	14.8
Cord blood	5	13.2	2	2.6	7	6.1
HLA and donor type, n. (%)
HLA ≥9/10, related donor	10	26.3	20	26.0	30	26.1
HLA ≥9/10, unrelated donor	15	39.5	43	55.8	58	50.4
HLA < 9/10, related donor	4	10.5	1	1.3	5	4.4
HLA < 9/10, unrelated donor	4	10.5	11	14.3	15	13.0
HLA 6/6, cord blood	2	5.3	1	1.3	3	2.6
HLA < 6/6, cord blood	3	7.9	1	1.3	4	3.5
Conditioning, n. (%)
Full intensity (myeloablative)	29	76.3	65	84.4	94	81.7
Reduced intensity	5	13.2	6	7.8	11	9.6
Reduced toxicity	4	10.5	6	7.8	10	8.7
TBI based	17	44.7	39	50.7	56	48.7
Busulfan based	12	31.6	25	32.5	37	32.1
Treosulfan based	4	10.5	7	9.1	11	9.6
Others	5	13.2	6	7.8	11	9.6
GvHD prophylaxis, n. (%)
Calcineurin inhibitor only	3	7.9	3	3.9	6	5.2
Calcineurin inhibitor + methotrexate	7	18.4	11	14.3	18	15.7
Calcineurin inhibitor + methotrexate + ATG	21	55.3	53	68.8	74	64.3
Other	7	18.4	10	13.0	17	14.8
GvHD grade at onset, n. (%)
0	38	100.0	-	-	38	33.0
I	-	-	36	46.8	36	31.3
II	-	-	37	48.0	37	32.2
III	-	-	4	5.2	4	3.5
IV	-	-	0	0.0	0	0.0